Stool-Based Colorectal Cancer Screening Test Performance Characteristics in Those With and Without Hemorrhoids
dc.contributor.author | Ebner, Derek W. | |
dc.contributor.author | Rushlow, David | |
dc.contributor.author | Mou, Joshua | |
dc.contributor.author | Porter, Kyle | |
dc.contributor.author | Finney Rutten, Lila J. | |
dc.contributor.author | Limburg, Paul | |
dc.contributor.author | Sancar, Feyza | |
dc.contributor.author | Imperiale, Thomas F. | |
dc.contributor.department | Medicine, School of Medicine | |
dc.date.accessioned | 2024-02-09T15:19:25Z | |
dc.date.available | 2024-02-09T15:19:25Z | |
dc.date.issued | 2023-07-19 | |
dc.description.abstract | Objective: To evaluate the effect of hemorrhoids on noninvasive stool test performance for colorectal cancer (CRC) screening. Patients and methods: We conducted a retrospective cohort study of test characteristics for the fecal immunochemical test (FIT) and the multitarget stool DNA (mt-sDNA) test, on the basis of hemorrhoid status, recorded at the time of colonoscopy, among patients enrolled in the pivotal prospective study for mt-sDNA that was conducted from June 2011, to May 2013. Test characteristics (sensitivity, specificity, positive, and negative predictive values) for FIT and mt-sDNA (performed < 90 days before colonoscopy) were stratified by the presence of hemorrhoids and compared. Results: Hemorrhoids were found in 51.7% (5163 of 9989) of the study cohort. Across all test characteristics, there were no statistically significant differences for FIT or mt-sDNA when stratified by hemorrhoid status. Analysis revealed mt-sDNA sensitivity of 44% and 41% for advanced precancerous lesions in nonhemorrhoidal and hemorrhoid patients, respectively (P=.41). The FIT sensitivity among the same lesion category was 24.9% in patients without hemorrhoids and 22.8% in those with hemorrhoids (P=.48). The mt-sDNA specificity was 86.4% in patients without hemorrhoids vs 87.7% in those with hemorrhoids (P=.67), although FIT specificity was 95.0% among patients without hemorrhoids vs 94.7% in those with hemorrhoids (P=.44). Conclusion: The presence of asymptomatic hemorrhoids did not adversely affect test performance in this large clinical study. These findings suggest that in the absence of overt gastrointestinal bleeding, FIT and mt-sDNA are options for CRC screening, irrespective of hemorrhoid status. | |
dc.eprint.version | Final published version | |
dc.identifier.citation | Ebner DW, Rushlow D, Mou J, et al. Stool-Based Colorectal Cancer Screening Test Performance Characteristics in Those With and Without Hemorrhoids. Mayo Clin Proc Innov Qual Outcomes. 2023;7(4):320-326. Published 2023 Jul 19. doi:10.1016/j.mayocpiqo.2023.06.003 | |
dc.identifier.uri | https://hdl.handle.net/1805/38373 | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | |
dc.relation.isversionof | 10.1016/j.mayocpiqo.2023.06.003 | |
dc.relation.journal | Mayo Clinic Proceedings: Innovations, Quality & Outcomes | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | en |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.source | PMC | |
dc.subject | Hemorrhoids | |
dc.subject | Colorectal cancer (CRC) screening | |
dc.subject | Fecal immunochemical test (FIT) | |
dc.title | Stool-Based Colorectal Cancer Screening Test Performance Characteristics in Those With and Without Hemorrhoids | |
dc.type | Article |